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Abstract
Background: Plasma glycosaminoglycan (GAG) measurements, when aggregated into diagnostic
scores, accurately distinguish metastatic clear-cell renal cell carcinoma (RCC) from healthy samples
and correlatewith prognosis. However, it is unknown if GAG scores can detect RCC in earlier stages or
if they correlate with prognosis after surgery.
Objective: To explore the sensitivity and speciﬁcity of plasma GAGs for detection of early-stage RCC
and prediction of recurrence and death after RCC surgery.
Design, setting, and participants: This was a retrospective case-control study consisting of a
consecutive series of 175 RCC patients surgically treated between May 2011 and February
2014 and 19 healthy controls.
Outcome measurements and statistical analysis: Plasma GAGs in preoperative and postoperative
RCC and healthy samples were measured using capillary electrophoresis with laser-induced ﬂuo-
rescence in a single blinded laboratory. A discovery setwas ﬁrst analyzed to update the historical GAG
score. The sensitivity of the new GAG score for RCC detection versus healthy subjects was validated
using the remaining samples. The correlation of the new GAG score to histopathologic variables,
overall survival, and recurrence-free survival was evaluated using nonparametric and log-rank tests
and multivariable Cox regression analyses.
Results and limitations: The RCC cohort included 94 stage I, 58 stage II–III, and 22 stage IV cases. In
the ﬁrst discovery set (n = 67), the new GAG score distinguished RCC from healthy samples with an
area under the receiver operating characteristic curve (AUC) of 0.999. In the validation set (n = 108),
the GAG score achieved an AUC of 0.991, with 93.5% sensitivity. GAG scores were elevated in RCC
compared to healthy samples, irrespective of and uncorrelated to stage, grade, histology, age, or
gender. The total chondroitin sulfate concentration was an independent prognostic factor for both
overall and recurrence-free survival (hazard ratios 1.51 and 1.25) with high concordance when
combined with variables available at pathologic diagnosis (C-index 0.926 and 0.849) or preopera-
tively (C-index 0.846 and 0.736). Limitations of the study include its retrospective nature and
moderate variability in GAG laboratory measurements.
Conclusions: Plasma GAGs are highly sensitive diagnostic and prognostic biomarkers in surgically
treated RCC independent of stage, grade, or histology. Prospective validation studies on GAG scores
for early detection, prediction, and surveillance for RCC recurrence are thus warranted.
Patient summary: In this study, we examined if a new molecular blood test can detect renal cell
carcinoma in the early stages and predict if the cancer might relapse after surgery.
The trial is registered on ClinicalTrial.gov as NCT03471897.
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Renal cell carcinoma (RCC) is the most common form of
kidney cancer, and the ninth most common cancer type in
the Western world, accounting for approximately 90
000 deaths globally every year [1,2]. RCC is largely
asymptomatic, so it is estimated that 20–40% of all cases
diagnosed are at the metastatic stage at presentation [3,4],
which is considered invariably incurable. Surgery is
generally offered as curative treatment in nonmetastatic
RCC. However, approximately 20% of all these cases
experience recurrence within 5 yr after surgery, and
90% of all recurrences involve metastatic disease [4]. Even
if up to 50% of recurrences are deemed potentially curable
(ie, local, solitary, or oligometastatic recurrence), it has been
estimated that currently only half of these cases are offered
local treatment with curative intent [5,6]. Despite these
data, there are no consensus guidelines on surveillance for
subgroups of the RCC population at high risk of recurrence,
and the standard technology for surveillance—medical
imaging—is not practical or cost-effective for detection of
recurrence over prolonged periods. The introduction of
minimally invasive biomarkers in the routine clinical
management of RCC could facilitate early detection,
prediction of recurrence, and surveillance of RCC, all cases
for which higher chances of cure can be expected. However,
despite extensive research [7], no plasma or urine
biomarker has been introduced into the clinical manage-
ment pathway for RCC [8,9].
We and others observed that genetic alterations specific
to clear cell RCC (ccRCC) correlated with marked metabolic
reprogramming in these cancer cells compared to other
common epithelial cancers [10–13]. Using a systems biology
approach, we observed in both retrospective and prospec-
tive series of metastatic ccRCC cases that the composition
and levels of plasma and urine glycosaminoglycans (GAGs)
were significantly altered compared to healthy samples
[14]. In addition, GAG scores correlated with progression-
free survival and overall survival (OS) in a prospective
cohort of patients with metastatic ccRCC [15]. However, it is
still unknown whether alterations in plasma and urine
GAGs are limited tometastatic ccRCC or correlatewith other
histopathologic variables in RCC. In addition, it is unknown
whether the GAG correlation with prognosis is limited to
ccRCC patients treated with systemic therapy or apply to
surgically treated RCC as well.
In this study, we profiled plasma GAGs in a large
retrospective consecutive series of patients with a
radiographic finding of a renal mass. Consistent with
our previous study, we also used a control group of healthy
volunteers for measurement of plasma GAGs. The
primary endpoints were the specificity and sensitivity of
plasma GAGs in the detection of RCC in preoperative
samples in comparison to healthy individuals. We further
analyzed how plasma GAGs varied according to stage,
grade, and RCC histology, and after surgery. Finally, we
estimated whether plasma GAGs correlate with prognosis
after surgery, assessed as OS and recurrence-free survival
(RFS).2. Patients and methods
2.1. Study design
This study is reported in compliance with the STARD and REMARK
guidelines. Additional information on the methods and a subset of
anonymized data aremade available in the Supplementary material. The
study was registered on ClinicalTrial.gov as NCT03471897.
We used a retrospective case-control design. Clinical data collection
and laboratory measurements were performed blinded to each other.
Inclusion criteriawere patients with radiographic ﬁnding of a renalmass
and healthy volunteers without any history of malignancy. The key
exclusion criterion was the absence of preoperative samples following
ﬁltering out of outliers and laboratory assay failures. Participants were
enrolled at the Memorial Sloan Kettering Cancer Center (New York, NY,
USA) between May 25, 2011 and February 18, 2014. Eligible participants
were identiﬁed from radiographic ﬁndings and formed a consecutive
series. For subjects with a renal mass, plasma samples were collected up
to 50 d before primary surgery. A convenience subcohort of these
subjects was followed longitudinally and samples were collected during
a follow-up visit between 1 and 30 mo after ﬁrst surgery. For healthy
volunteers, plasma samples were collected from relatives of cancer
patients and formed a random convenience cohort.
Ethics permission for the study was obtained from the institutional
review board at the Memorial Sloan Kettering Cancer Center on
November 5, 2012 (#12-237).
2.2. GAG measurements
Whole blood samples were collected in EDTA-coated tubes. The tubes
were centrifuged (1100  g for 10 min) and the plasmawas extracted and
collected in a separate tube. All samples were stored at 80 C. Samples
were shipped in dry ice. Laboratory measurements of the GAG proﬁle
quantiﬁed 19 independent properties: the total concentration of
chondroitin sulfate (CS; mg/ml); total concentration of heparan sulfate
(HS; mg/ml); total concentration of hyaluronic acid (HA; mg/ml); mass
fraction of eight CS sulfation patterns (0s CS, 2s CS, 6s CS, 4s CS, 2s6s CS,
2s4s CS, 4s6s CS, and Tris CS); and the mass fraction of eight HS sulfation
patterns (0s HS, 2s HS, 6s HS, Ns HS, Ns6s HS, Ns2s HS, 2s6s HS, and Tris
HS). In addition, the charge of CS and HS and three additional CS ratios
were calculated (6s/0s CS, 4s/0s CS, and 4s/6s CS). The overall GAG proﬁle
therefore consisted of 24 properties. These properties were measured
using capillary electrophoresis with laser-induced ﬂuorescence in a
single blinded laboratory, as previously described [16–18].
2.3. Exploratory data analysis
Principal component analysis (PCA) and unsupervised hierarchical
clustering [19] were performed for all preoperative RCC and healthy
control samples using either CS-only or HS-only properties. The
enrichment of selected histopathologic features in the emerging clusters
was tested using the proportional equality test.
2.4. GAG scores
Two different scoring systems for selected properties in the plasma GAG
proﬁle were used: the previously developed GAG score [14] and the new
GAG score derived in this study. For diagnostic use, the index test was
deﬁned as the test that classiﬁes a subject as having RCC if the formula
for the previous GAG score in a sample from that subject returns a score
greater than the prespeciﬁed cutoff for plasma GAG scores. The cutoff
was the numerical value maximizing the accuracy in the classiﬁcation
RCC versus healthy samples as determined in our previous study
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versus healthy controls from this cohort or versus healthy controls from
historical cohorts [14]. The reference standard for deﬁning a subject as
having RCC was the pathology report, while healthy status was self-
reported. Index test results were not available to the assessors of the
reference standard. A prespeciﬁed variation of the previously developed
GAG score omitting the Ns HS term was also tested.
In the case of the new GAG score, the formula was derived using
penalized regressionwith Lasso [20], as previously described [14]. To this
end, 38% of the total preoperative RCC samples were randomly selected
to form a discovery set, together with the healthy controls from this or
historical cohorts. The optimal cutoff for the new GAG score was then
computed. For validation, the index test was redeﬁned in terms of the
new GAG score and cutoff and tested on the remaining 62% of the total
preoperative RCC samples. Note that only the index test sensitivity could
be validated in this manner.
2.5. Statistical analysis
The area under the receiver operating characteristic curve (AUC),
sensitivity, speciﬁcity, and accuracy were computed for classiﬁcation of
individuals as RCC versus healthy as per the reference standard according
to the index test. Missing data in the index test caused by laboratory
assay failurewere omitted. No othermissing or indeterminate data in the
index test and reference standards were observed.
The difference in each of the GAG properties included during feature
selection between RCC and healthy groups, adjusted by cohort, was
assessed using Bayesian estimationwith a bivariate linear model [21,22].
The association with tumor grade, stage, size, and histological
subtype was assessed by applying a Mann-Whitney test or t test to the
linear regression coefﬁcient for categorical or continuous variables,
respectively. Statistical signiﬁcance was set to p < 0.05. The minimum
study sample size was 156 consecutive patients and 10 healthy subjects
as determined by power calculations.
2.6. Survival analysis
Survival was calculated as the time between the date of ﬁrst surgery and
the event time. The event time was deﬁned as right-censoring (date of
last follow-up without the event), date of death in the case of OS, and
date of recurrence in the case of RFS. Recurrence was deﬁned as
radiological evidence of one or more metastatic lesions. The end of the
follow-up period was November 2017. The study was not powered
speciﬁcally for survival analysis.
Univariate and multivariate survival analyses were performed by
ﬁtting a Cox proportional hazards model to relevant clinical variables
and the log-rank statistical test was applied to determine the regression
signiﬁcance. We checked for severe overﬁtting by performing internal
validation of Lasso-penalizedmultivariatemodels for OS and RFS using a
bootstrapping algorithm (1000 bootstraps) to correct the original
Somers’ D rank correlation (Dxy) statistics. The corrected Dxy is
transformed into the concordance index Cindex ¼ Dxy2 þ 0:5
 
.
One of the constituent GAG properties of the new GAG score, namely
the total CS concentration (CStot), was also used to dichotomize patients
into two groups: low versus high score. Kaplan-Meier survival curves
were ﬁtted for the two groups, and the statistical signiﬁcance for survival
difference was evaluated using the log-rank test, with
p < 0.05 considered signiﬁcant.
2.7. Reproducibility analysis
Technical replicateswere performed on 80 samples from a quasi-random
subset of 40 patients to encompass a pair of preoperative and
postoperative samples for each patient while balancing RCC histologiesand the presence ofmetastases at surgery in the subset. The coefﬁcient of
variability and least-squared linear regressionwas computed for the new
GAG score in the original batch (ﬁrst batch) versus the replicated batch
(second batch).
3. Results
3.1. Patient characteristics
In total, 237 subjects were retrospectively enrolled for this
study, 218 patients and 19 healthy volunteers, for a total of
470 plasma samples encompassing both preoperative and
postoperative samples (Supplementary Figure 1). We
excluded 13 samples (3%) because of laboratory assay
failure and seven (1.5%) because they met the criteria as
outliers. We further excluded 24 patients (11%) because the
preoperative samples were either too old or not available.
For three patients, two preoperative samples were obtained
within 50 d from surgery, the oldest ofwhichwas discarded.
Overall, 19 healthy volunteers and 194 patients with
preoperative samples were included in the study. Of the
194 patients, 152 (78%) had at least one postoperative
sample. The median time between surgery and postopera-
tive sample collection was 32 d (interquartile range [IQR]
26–38, range 4–222). Overall, 365 samples were included in
the study.
The median age at diagnosis in the patient cohort was
60 yr (IQR 52–67). The cohortwas predominantly composed
of males (69%; 134 males vs 60 females) and white
Americans (90%). The most common pathologic diagnosis
was RCC (n = 175 patients; 90%), followed by oncocytoma
(n = 7; 4%) and angiomyolipoma (n = 6; 3%). There were two
cases with other benign renal masses (1 medullary fibroma
and 1 mixed epithelial stromal tumor) and four cases of
other malignant renal masses, including three urothelial
cell carcinomas. Since the rate of other renal masses was
substantially lower than anticipated, this study did not
achieve the statistical power to use these cases as controls,
which were therefore excluded from subsequent analyses.
The median age in the healthy cohort was 55 yr (IQR 50–60)
and the group included six males and 13 females. Age was
not significantly different between the cohorts (p = 0.173;
Mann-Whitney test), but the proportion of males was
significantly higher in the patient group than in the healthy
group (p = 0.002; proportion equality test). Baseline char-
acteristics for all the subjects are shown in Table 1.
Limited to the subcohort of 175 RCC cases, the
demographic characteristics were similar to those for the
patient cohort (Table 2). The most common histological
subtype was ccRCC (n = 124; 71%). Of the remaining 51 non-
ccRCC (nccRCC) cases, the most common histological
subtype was papillary RCC (n = 26), followed by chromo-
phobe RCC (n = 17). Most RCC cases involved localized
disease (stage I; n = 94; 54%), with the vast majority of
tumors of <4 cm in size (pT1a; n = 70). The remaining RCC
cases were predominantly locally advanced disease (stage II
or III; n = 58). Finally, there were 22 cases of advanced
disease (stage IV, including 1 pT4N0M0). The baseline
characteristics for the RCC subcohort are shown in Table 2.
Table 2 – Demographic and clinicopathological characteristics of
the subcohort of patients with renal cell carcinoma (RCC)
Characteristic RCC
(n = 175)
Median age, yr (interquartile range) 60 (52–67)
Gender (n)
Female 48
Male 127
Ethnicity (n)
White 159
African American 7
Asian American 2
Other/not available 7
Histological subtype (n)
Clear cell 124
Non–clear cell 51
Chromophobe 17
Mucinous tubular and spindle cell 2
Papillary type I 19
Papillary type II 3
Papillary (unspeciﬁed) 4
Unclassiﬁed 6
Median tumor size, cm (interquartile range) 4.5 (2.9–7)
pT stage (n)
T1 94
T1a 70
T1b 24
T2 7
T2 (unspeciﬁed) 3
T2a 2
T2b 2
T3 72
T3 (unspeciﬁed) 3
T3a 57
T3b 11
T3c 1
T4 1
Not available 1
pN stage (n)
N0 61
N1 7
NX 107
pM stage (n)
M0 152
M1 22
Not available 2
TNM stage, (n)
Stage I 94
Stage II 6
Stage III 52
Stage IV 22
Not available 1
Grade (n)
Not available 35
Fuhrman nuclear grade 122
2 39
3 61
4 22
Other grading system 18
High 7
Low 11
Table 1 – Demographic and clinicopathological characteristics of
the retrospective cohort of patients and healthy volunteers
Characteristic Patients Healthy
(n = 194) (n = 19)
Median age, yr (interquartile range) 60 (52–67) 55 (50–60)
Gender (n)
Female 60 13
Male 134 6
Race (n)
White 174 0
African American 9 0
Asian American 3 0
Other/not available 8 19
Diagnosis (n)
Renal cell carcinoma 175
Oncocytoma 7
Angiomyolipoma 6
Urothelial cell carcinoma 3
Other benign 2
Other malignant 1
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controls
The GAG profile, which encompasses the total concentra-
tion, disaccharide composition, and charge for CS, HS, and
HA (total of 24 properties), was measured in plasma
samples using capillary electrophoresis with laser-induced
fluorescence in a single blinded laboratory, as previously
described [16–18].
We performed PCA to ascertain in an unbiased fashion
how similar the CS and HS profiles were across preoperative
RCC and healthy samples (Fig. 1A). The PCA plot shows that
the CS profiles in preoperative RCC samples tended to
cluster as a separate group, with limited overlap with
samples obtained from healthy volunteers. By contrast, the
HS profile in RCC samples partly overlapped with healthy
samples. However, we also observed a tail of RCC samples
with a HS profile that substantially deviated from the
healthy samples. This analysis suggests that there are
differences in plasma CS profile between samples from
healthy subjects and most RCC samples.
We used unsupervised hierarchical clustering based on
the between-sample CS or HS profile correlation to validate
the PCA results and to highlight the GAG properties
contributing to the separation of RCC from healthy subjects
(Fig. 1B). In agreement with PCA, unsupervised clustering
confirmed a separation in the CS profile of healthy subjects
from RCC samples. Seventeen of 19 healthy samples (89%)
formed a cluster together with seven of 175 RCC samples
(4%) that were markedly separated from other clusters
containing 168 of 175 RCC samples (96%) and two of
19 healthy samples (11%). It is noteworthy that these other
clusters displayed heterogeneous patterns of CS properties,
with no single CS property being consistently higher or
lower than for the group of healthy subjects. This analysis
could not readily associate the diversity of patterns to RCC
stage, grade, or histology. Despite this heterogeneity, in
general the CS profile of RCC samples featured one or more
of the following alterations: a lower fraction of unsulfatedCS (0s CS); a higher fraction of 4-sulfated CS (4s CS); a higher
CS charge; or a higher total CS concentration. In line with
PCA, the HS profiles of healthy subjects did not form a
separate group when clustering was performed together
with RCC samples. However, this analysis highlighted an
isolated cluster with a statistically significant enrichment of
[(Fig._1)TD$FIG]
Fig. 1 – Clustering analysis of plasma chondroitin sulfate (CS) and heparan sulfate (HS) profiles for 175 preoperative renal cell carcinoma (RCC) samples
and 19 samples from healthy subjects. (A) Principal component analysis (PCA) based on quantification of the CS and HS profile in plasma samples from
RCC patients and healthy subjects. Each point represents an individual sample. The percentage indicates the proportion of variance explained along
the axis of each principal component (PC). The ellipses delimit the area in which samples belonging to a certain group are expected to be located at a
95% confidence level assuming a multivariate t distribution. (B) Unsupervised hierarchical clustering based on between-sample correlation in the CS
and HS profiles. Each row represents an individual CS or HS property. Each column represents a sample. The annotation above provides information
on the principal diagnosis, the Fuhrman nuclear grade (if applicable and available) and the TNM stage. For each row, values for the corresponding CS
or HS property were normalized as z scores.
E U RO P E AN URO L OGY ONCO L OGY 1 ( 2 018 ) 3 6 4 – 37 7368RCC samples with no healthy samples included (p = 0.03;
proportion equality test). This cluster featured notably
higher Ns HS and HS charge. We did not observe any
association with stage, grade, or histology for RCC samples
specifically belonging to this cluster.3.3. Plasma GAG scores to distinguish RCC from healthy
subjects
We previously developed a plasma GAG score that
distinguished metastatic ccRCC from healthy subjects with
EU RO P E AN U RO LOGY ONCO LOGY 1 ( 2 018 ) 3 6 4 – 37 7 369AUC = 1 and 92.6% accuracy in two historical cohorts from
Sweden and Italy [14]. We noted that this GAG score only
partly matched the alterations observed in the present
series. For example, in our previous study the Ns HS fraction
was consistently low in metastatic ccRCC; here, we
observed extremely high Ns HS fractions in some RCC
samples. In addition, the 6s CS fraction was high in
metastatic ccRCC; here, the healthy samples had 6s CS
levels comparable to many RCC samples. Accordingly, the
published score underperformed in this data set (80%
sensitivity, 42% specificity; AUC 0.738, 95% confidence
interval [CI] 0.627–0.850; Supplementary Table 1), even
when Ns HS was omitted from the score calculation (AUC
0.804, 95% CI 0.705–0.904; Supplementary Fig. 2A). We
observed that the performance of the published score in this
data set was affected by high 6s CS fractions in the healthy
group and the presence of a cluster of RCC samples with
high Ns HS fraction. Were the historical healthy cohorts
used as control group, the AUC for the published score
would be 0.909 (95% CI 0.867–0.951) with 80% sensitivity
and 92% specificity. Omission of Ns HS from the scorewould
achieve an AUC of 0.999 (95% CI 0.998–1; Supplementary
Fig. 2B).
Therefore, we sought to redefine the formula to calculate
the GAG score so that: (1) it incorporated the GAG alterations
observed in the current cohort in addition to those observed
in the historical Swedish and Italian cohorts; and (2) it was
robust to variability in the control healthy group. To this end,
we designed a discovery set comprising 67 preoperative RCC
versus 19 healthy samples from the current cohort and all
historical RCC and healthy samples from the two published
cohorts (Swedish cohort: 26 RCC vs 20 healthy; Italian
cohort: 23 RCC vs 5 healthy). The RCC samples from the
current cohort represented a random selection of the total
samples (38% of total preoperative RCC samples) which had
been included in the interim analysis for this study. The
following GAG properties were considered given their
association with RCC in the current cohort or the historical
cohorts: the 6s CS fraction, the 6s/4s CS ratio (normalized
here by total 4s and 6s CS), the total CS concentration, the CS
charge, and the 0s/Ns HS ratio (on a log2 scale to increase
robustness). When adjusting for the cohort, all these
properties were significantly different between RCC and
healthy samples (Table 3, Fig. 2).
The final consensus formula consisted of five GAG
properties:Table 3 – Difference in selected GAG properties between RCC (n = 116)
cohorts) according to Bayesian estimation
GAG property MD (95% HDI) Effe
6s CS 1.59 (0.92–2.29)
6s/(4s + 6s) CS 0.08 (0.06–0.10)
CStot 6.04 (1.80–7.78)
CS charge 0.13 (0.11–0.16)
log2
0s
Nsþ0sHS
 
0.12 (0.04–0.22)
GAG = glycosaminoglycan; RCC = renal cell carcinoma; MD = modal difference betw
chain Monte Carlo; ROPE = region of practical equivalence; CS = chondroitin sulfa
a Differences for which the fraction of MCMC samples in ROPE was below 5% arePlasma score ¼ 3
10
½6s CS þ 25 ½6sCS½6sCS þ ½4s Cs
þ 6
10
CStot þ 13  CS charge
þ 6
100
log2 1þ
½0sHS
½0sHS þ ½NsHS
 
;
where [6s CS] is the mass fraction of 6-sulfated CS, [4s CS] is
themass fraction of 4-sulfatedCS, [NsHS] is themass fraction
ofN-sulfatedHS, [0sHS] is themass fraction of unsulfatedHS,
CStot is the total concentration of CS in mg/ml, and CS charge
is the charge-weighted sum of all CS mass fractions.
The new plasma GAG score achieved an AUC of 0.999
(95% CI 0.997–1), with a maximum accuracy of 98.9%
(1 false negative) equivalent to 94.7% specificity and 100%
sensitivity at an optimal cutoff score of 0.87 (Fig. 3,
Supplementary Table 1). In accordance with the analysis
above, the new GAG score was elevated for all RCC samples
irrespective and seemingly independently of tumor stage,
grade, and histology. The new GAG score performed
similarly in our historical cohorts, with AUC = 1 for the
Italian cohort (23 stage IV RCC vs 5 healthy subjects;
Supplementary Fig. 3) and AUC = 0.988 (95% CI 0.964–1) for
the Swedish cohort (26 stage IV RCC vs 20 healthy subjects;
Supplementary Fig. 3).
We then evaluated the new GAG score in the remaining
group of 108 preoperative RCC samples (62% of total), which
formed a validation set. Quantification of the GAG profile in
these samples was performed after and blind to the
formulation of the new score. RCC patients in the validation
set were older (median 62 yr, IQR 55–68) than in the
discovery set (median 55 yr, IQR 48–63; p = 0.002), but
there were no other significant differences in the baseline
characteristics (Supplementary Table 2). The newGAG score
achieved an AUC of 0.991 (95% CI 0.977–1) in the validation
set. At the prespecified cutoff, the validated sensitivity was
93.5% (Fig. 3, Supplementary Table 1). Note that the
specificity could not be validated because the control
healthy group was the same as in the discovery set.
3.4. Correlation between plasma GAG score and
clinicopathologic features
We explored whether the new GAG score or any of its
constituent GAG properties correlated with clinicopatho-
logic features of the 175 preoperative RCC samples. The newand healthy samples (n = 44) from the discovery set (across three
ctive MCMC samples MCMC samples in ROPE (%) a
23 010 0.01
22 228 0.03
19 045 0.02
11 857 0.00
13 189 2.35
een RCC and healthy samples; HDI = high-density interval; MCMC = Markov
te; HS = heparan sulfate.
considered statistically significant.
[(Fig._2)TD$FIG]
Fig. 2 – Selected glycosaminoglycan properties in plasma samples in the discovery set, comprising 38% of the current cohort (RCC 67, healthy 19) and
two historical cohorts from Sweden (RCC 26, healthy 20) and Italy (RCC 23, healthy 5) [14]; see also Table 3. RCC = renal cell carcinoma; CS = chondroitin
sulfate; HS = heparan sulfate; tot = total.
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tumor stage, grade, size, or histology (Table 4). However,
two of its constituent GAG properties showed a weak
correlation with tumor size and/or histology. The CS charge
was shifted towards higher values in nccRCC (9.8% mean
increase; Mann-Whitney test p = 0.05) and was negatively
correlated with tumor size (r = 0.27; p = 0.001 in a t test
on the linear regression coefficient; Supplementary Fig. 4).The 0s/Ns HS ratio was also negatively correlated with
tumor size (r = 0.20; p = 0.008; Supplementary Fig. 4).
The new GAG score was not significantly associated with
age (r = 0.04; p = 0.561), gender (4.28% increase in males;
p = 0.692), or fasting (1.4% increase with fasting; p = 0.766;
n = 80 with available data [46% fasting]). Of all the
constituent GAG properties, 6s CS (r = 0.25; p < 0.001)
and 6s/4s CS ratio (r = 0.25, p < 0.001) showed a positive
[(Fig._3)TD$FIG]
Fig. 3 – (A) Boxplot of the new plasma glycosaminoglycan (GAG) score for 19 healthy samples versus 67 preoperative renal cell carcinoma (RCC)
samples comprising the discovery set versus 108 preoperative RCC samples comprising the validation set. The horizontal line indicates the cutoff score
corresponding to maximum accuracy for the discovery set. (B) Corresponding receiver operating characteristic curve for classification for the discovery
and validation sets. Note that 12 samples with scores greater than 2 in the validation set were omitted from display to prevent shrinkage of the plot.
Table 4 – Correlation between the new plasma GAG score or any of its constituent GAG properties with clinicopathological features in
preoperative RCC (N = 175) or ccRCC in the case of FNG (n = 121)
GAG property Stage FNG Size in cm (n = 175) Histology
LA/A (n = 80) vs
localized (n = 94)
G3 (n = 82) vs G2
(n = 39)
nccRCC (n = 51) vs
ccRCC (n = 124)
Shift p value Shift p value r p value Shift p value
6s CS 0.0006 0.8836 0.0060 0.4261 0.1365 0.0717 0.0060 0.3460
6s/(4s + 6s) CS 0.0097 0.5221 0.0132 0.4591 0.0361 0.6357 0.0285 0.0784
CStot 0.0377 0.5349 0.1003 0.0956 0.1353 0.0742 0.0697 0.2889
CS charge 0.0260 0.1658 0.0129 0.6873 0.2685 0.0003 0.0389 0.0496
log2
0s
Nsþ0sHS
 
0.0002 0.1311 0.0002 0.1205 0.1991 0.0083 0.0003 0.0707
New GAG score 0.0044 0.9242 0.0689 0.2734 0.0355 0.6413 0.0770 0.1788
GAG = glycosaminoglycan; RCC = renal cell carcinoma; cc = clear cell; ncc = non–clear cell; FNG = Fuhrman nuclear grade; LA/A = locally advanced or advanced;
CS = chondroitin sulfate; HS = heparan sulfate.
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age, gender, or fasting were observed.
3.5. Correlation of the new GAG score and its constituent
properties with OS
We investigatedwhether the preoperative score or any of its
constituent GAG properties correlated with RCC prognosis.
Prognosis was first evaluated in terms of OS after surgery.
OS was computed for all 175 RCC patients. There were
19 deaths (11%) in this population over median follow-up of
53mo (IQR 37–60). The estimated 3-yr OSwas 90.4% (95% CI
85.9–95.1%). We built a univariate Cox proportional hazards
model for each of the following variables: age, tumor size,
tumor grade (G3/G4/high vs G2/low), tumor TNM stage (III/
IV vs I/II), type of nephrectomy (radical vs partial), surgical
margins (positive vs negative), Stage, Size, Grade, and
Necrosis (SSIGN) score, and the new GAG score and its five
constituent GAG properties (6s CS, 6s/4s CS ratio, CStot, CS
charge, 0s/Ns HS ratio). Tumor size, grade, and stage, radicalnephrectomy, positive surgical margins, and the SSIGN
score were significantly associated with OS (Table 5). In
addition, three of five GAG properties in the new GAG score
were also significantly associated with OS, even though the
new GAG score did not reach significance by itself (HR 1.25;
p = 0.08). Starting from the variables significantly associated
with OS in univariate analysis, we built a multivariate Cox
proportional hazards model. This model was cross-validat-
ed using penalized Lasso, which returned a multivariate
model consisting of four variables: tumor size, SSIGN score,
surgical margins, and CStot. Of these, CStot (HR 1.51;
p < 0.001) and SSIGN score were independent prognostic
factors for OS (HR 5.04; p < 0.001; Table 5). The concor-
dance index for this model was 0.934; after correction for
optimism, the cross-validated C-index was 0.926.
We further investigated the possibility of groupingpatients
according to low versus high CStot for differential association
with OS. We found an optimal cutoff of 0.914 for the
preoperative CStot. Forty-one patients (23%) had a CStot
above the cutoff (high CStot), while 134 belonged to the low
[(Fig._4)TD$FIG]
Fig. 4 – Kaplan-Meier curves for overall survival for low versus high risk according to (A) the preoperative total chondroitin sulfate (CStot) value alone
and (B) the preoperative CStot value combined with tumor size >5 cm among 175 patients with renal cell carcinoma.
Table 5 – Association of clinical factors with overall survival in the preoperative renal cell carcinoma population (n = 175) a
Factor N [n deaths] Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age 175 1.23 (0.76–1.98) 0.391
Tumor size 175 2.53 (1.77–3.62) <0.001 1.13 (0.56–2.29) 0.723
Tumor grade
Grade 2 or low 50 [2] 1
Grade >2 or high 90 [14] 8.42 (1.11–6.41) 0.039
Not available 35
TNM stage
I or II 101 [3] 1
III or IV 74 [16] 11.67 (2.68–5.08) 0.001
Nephrectomy type
Partial 113 [2] 1
Radical 62 [17] 34.8 (4.6–261.6) <0.001
Surgical margins
Negative 170 [16] 1
Positive 5 [3] 5.18 (2.12–12.6) <0.001 4.06 (0.75–22) 0.105
SSIGN score 118 3.37 (2.21–5.13) <0.001 5.04 (2.53–10) <0.001
New GAG score 175 1.25 (0.97–1.62) 0.080
6s CS 175 0.35 (0.14–0.91) 0.032
6s/(4s + 6s) CS 175 0.62 (0.34–1.14) 0.125
CStot 175 1.34 (1.11–1.62) 0.002 1.51 (1.19–1.93) <0.001
CS charge 175 0.44 (0.24–0.80) 0.008
log2
0s
Nsþ0sHS
 
175 0.80 (0.52–1.22) 0.293
HR = hazard ratio; CI = conﬁdence interval; GAG = glycosaminoglycan; SSIGN = Stage, Size, Grade, and Necrosis; CS = chondroitin sulfate; HS = heparan sulfate.
a In multivariate analysis, patients with missing data for any of the selected covariates were omitted (n = 57). Continuous variables were centered to the mean and
scaled to the standard deviation.
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revealed that patients in the low group had longer OS than
those in the high CStot group (HR 3.6; p = 0.002; Fig. 4). The 3-
yr OSwas 80.4% (95% CI 68–95%) for the high group and 93.4%
(95% CI 89–98%) for the low CStot group. Next, we explored
whether other clinical variables could be used to construct a
parsimonious preoperative stratification to identify theminimum number of patients at high risk of death. Note
that most variables in Table 4 are not available preoperatively,
except for tumor size and age. We therefore summed CStot
with the tumor size centered to 5 cm (equivalent to the cutoff
used to calculate the SSIGN score) and searched for an optimal
cutoff for grouping patients into low versus high risk
categories. The optimal cutoff was determined to be 2.37. This
EU RO P E AN U RO LOGY ONCO LOGY 1 ( 2 018 ) 3 6 4 – 37 7 373cutoff assigned only 28 patients (16%) to the high risk
category, and 147 patients (84%) to the low risk category. This
proportion is close to the proportion of deaths observed in this
cohort (11%). Accordingly, Kaplan-Meier survival plots
revealed that patients in the low risk group had significantly
longer OS than those in the high risk group (HR 10;
p =<0.001; Fig. 4). The 3-yr OS was 59.2% (95% CI 43–82%)
in the high risk group versus 96.2% (95% CI 93–99%) in the low
risk group. We verified that this stratification reached higher
statistical significance than if the stratification were solely
based on tumor size (p = 8 1010 versus p = 9 107) owing
to the less parsimonious classification of patients in the high
risk category when only tumor size is considered (n = 71 vs
104 patients had tumor size >5 cm). This strengthens the
conclusion that CStot provides additional prognostic informa-
tion for OS compared to tumor size alone. Finally, we built a
multivariate Coxmodel using CStot and tumor size as the only
preoperative variables to regress OS. The C-index for this
model was 0.857; after correction for optimism, the C-index
was 0. 846.
3.6. Correlation of the new GAG score and its constituent
properties with RFS
We repeated the analysis above for RFS, with recurrence
defined as radiological evidence of any distant metastatic
lesion(s) any time after surgery.
RFS was estimated for the subset of 152 RCC patients
with no evidence of distant metastases before surgery. Note
that this excluded all 22 pM1 cases and one pT1N0M0 case
who developed metastases between first radiologicalTable 6 – Association of clinical factors with recurrence-free survival in
(n = 152) a
Factor N [n deaths] Un
HR (95% CI)
Age 152 1.54 (0.76–1.98)
Tumor size 152 1.74 (1.77–3.62)
Tumor grade
Grade 2 or low 47 [3] 1
Grade >2 or high 71 [13] 3.15 (1.11–6.41)
Not available 34 –
TNM stage
I or II 98 [4] 1
III or IV 54 [15] 7.74 (2.68–5.08)
Nephrectomy type
Partial 111 [5] 1
Radical 41 [14] 8.48 (3.05–23.6)
Surgical margins
Negative 149 [18] 1
Positive 3 [2] 2.75 (0.66–11.5)
Leibovich score 98 3.26 (2.21–5.13)
New GAG score 152 1.34 (0.97–1.62)
6s CS 152 0.78 (0.14–0.91)
6s/(4s + 6s) CS 152 0.84 (0.34–1.14)
CStot 152 1.37 (1.11–1.62)
CS charge 152 0.83 (0.24–0.80)
log2
0s
Nsþ0sHS
 
152 0.67 (0.52–1.22)
HR = hazard ratio; CI = conﬁdence interval; GAG = glycosaminoglycan; RCC = rena
a In multivariate analysis, patients with missing data for any of the selected cova
and scaled to the standard deviation.diagnosis and surgery. There were 19 recurrences (12.5%)
in this population and themedian follow-upwas 51mo (IQR
36–57). The estimated 3-yr RFS was 90.8% (95% CI 86–96%).
We built a univariate Cox proportional hazards model for
each of the variables previously considered for OS, except
the SSIGN scorewas replaced by the Leibovich score. Tumor
size, stage, radical nephrectomy, and the Leibovich score
were significantly associatedwith RFS (Table 6). In addition,
two of five GAG properties in the new GAG score as well as
the new GAG score itself were also significantly associated
with RFS. Starting from the variables significantly associat-
ed with RFS in univariate analysis, we built a multivariate
Cox proportional hazards model. This model was cross-
validated using penalized Lasso, which returned a multi-
variate model consisting of three variables: nephrectomy
type, the Leibovich score, and CStot. The latter two were
independently associated with RFS with similar prognostic
value (HR 2.25 and 1.25; p = 0.045 and 0.054 respectively;
Table 6). The C-index for this model was 0.864; after
correction for optimism, the cross-validated C-index was 0.
849. In analogy to OS, we investigated if it were possible to
group patients into low versus high CStot for differential
associationwith RFS.We found an optimal cutoff of 1 for the
preoperative CStot. Twenty-one patients (14%) had CStot
above the cutoff (high CStot), while 131 belonged to the low
CStot group. Kaplan-Meier survival plots revealed that
patients in the low CStot group had longer RFS than those
in the high CStot group (HR 2.7; p = 0.046; Fig. 5). The 2-yr
RFS was 79.1% (95% CI 63–100%) for the high CStot group
versus 94.4% (95% CI 90–98%) for the low CStot group.
We sought to construct a parsimonious preoperativethe preoperative population with nonmetastatic renal cell carcinoma
ivariate Multivariate
p value HR (95% CI) p value
0.085
0.001
0.073
<0.001
<0.001 1.23 (0.70–16.7) 0.130
0.165
<0.001 2.25 (1.01–5.02) 0.045
0.013
0.376
0.489
0.003 1.31 (1.00–1.57) 0.054
0.447
0.045
l cell carcinoma; CS = chondroitin sulfate; HS = heparan sulfate.
riates were omitted (n = 54). Continuous variables were centered to the mean
[(Fig._5)TD$FIG]
Fig. 5 – Kaplan-Meier curves for recurrence-free survival for low versus high risk according to (A) the preoperative total chondroitin sulfate (CStot)
value alone and (B) the preoperative CStot combined with tumor size >5 cm among 152 patients with nonmetastatic renal cell carcinoma.
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high risk of recurrence by factoring in tumor size as the only
other significant clinical variable available before surgery.
We thus summed CStot and the tumor size centered to 5 cm,
and found an optimal cutoff of 2.05. This cutoff assigned
only 34 patients (22%) to the high risk category, as opposed
to 118 patients (78%) to the low risk category. This
proportion is close to the proportion of recurrences
observed in this cohort (12.5%). Accordingly, Kaplan-Meier
survival plots revealed that patients in the low risk group
had significantly longer RFS than those in the high risk
group (HR 6.3; p = <0.001; Fig. 5). The 2-yr RFS was 78.8%
(95% CI 66–94%) in the high risk group versus 96.4% (95% CI
93–100%) in the low risk group.We also verified in this case
that the proposed stratification reached higher statistical
significance than if the stratification were solely based on
tumor size (p = 9  105 vs. p = 6  104) possibly owing to
the less parsimonious classification of patients in the high
risk category when only tumor size is considered (n = 49 vs
103 patients had tumor size>5 cm). As in the case of OS, we
built a multivariate Cox model using CStot and tumor size as
the only preoperative variables to regress RFS. The C-index
for this model was 0.762; after correction for optimism, the
C-index was 0.742.
3.7. Change in the new GAG score and its constituent properties
after surgery
We finally investigated whether the new GAG score
changed after surgery. Of the 152 patients with at least
one postoperative sample, 139 had RCC at pathologic
evaluation. For this analysis, we computed the change in
new GAG score for each RCC patient between the
preoperative samples and the first available postoperativesample. This difference in new GAG score was widely
variable across patients, with an increase in score observed
for 53% of cases and a decrease for 47% after surgery. The
direction of change did not seem to correlate with patient
outcomes as assessed by evidence of recurrence within 2 yr
from surgery (Supplementary Fig. 5).
To test whether the lack of coherent GAG score changes
after surgery was attributable to technical noise in the
measurement of the plasma GAG profile, we replicated the
GAG measurements in a quasi-random subset of 40 pairs of
postoperative and preoperative RCC samples for a total of
80 samples assessed in duplicate. The reproducibility of the
new GAG score across the 80 duplicates was moderately
high, with a coefficient of variation (CV) of 18.5% 	 15%.
Importantly, all 40 preoperative samples in the second
batch were correctly classified as RCC and not healthy given
that the corresponding new GAG score was always above
the prespecified cutoff (Supplementary Fig. 6). However, the
correlation between the new GAG scores for the 80 samples
in the first versus the second batchwas low, mainly because
most of the RCC samples had scores in a narrow range. The
preoperative versus postoperative difference in GAG score
was sensitive to this low correlation between batches and
yielded no correlation in the direction of change before and
after surgery between the two batches (odds ratio 0.7;
p = 0.75). This lack of coherent changes can probably be
explained by the fact that measurement errors are
compounded when calculating a difference between GAG
scores as opposed to calculating the absolute GAG score, for
which the reported CV was 18.5%. Overall, this analysis
seems to indicate that the new GAG score does not
normalize after surgery, even though a conclusive experi-
ment should be conducted once the technical variability in
the measurement of plasma GAGs is sufficiently low.
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In this study, we profiled plasma GAGs in preoperative
samples from a retrospective consecutive series of 175 RCC
patients referred for surgery to investigate whether plasma
GAGs are diagnostic and prognostic in nonmetastatic RCC.
We report that a new GAG score, developed on the basis of
our previously published GAG score for metastatic ccRCC
[14], had 93.5% sensitivity and 94.7% specificity for
discriminating RCC from healthy samples, with the sensi-
tivity estimate independently validated among 108 RCC
patients. The new GAG score was independent and
uncorrelated to tumor stage, grade, size, and histology,
and was not confounded by either age or gender. One of the
constituent properties in the new GAG score, namely CStot,
was an independent prognostic factor for OS and RFS.When
combinedwith tumor size, the only other significant clinical
variable available preoperatively, CStot provided a tool for
parsimonious stratification of patients as having high
versus low risk for metastatic recurrence or death, with
high concordance.
These results expand our knowledge on the diagnostic
and prognostic potential of plasma GAGs in RCC, which was
so far limited to metastatic ccRCC in our previous studies
[14,15]. Other groups reported that GAGs are significantly
altered in RCC tissue compared to normal adjacent tissues,
confirming the role of the tumor in altering the concentra-
tion and composition of GAGs [23–25]. Although previous
studies revealed alterations in GAG concentrations in urine
from patients with localized RCC [25,26], there is very
limited information on the effects of RCC on GAG
compositions and, to the best of our knowledge, no other
studies on the effects of RCC on GAG concentrations and
compositions in plasma. This is partly explained by the
complexity of plasma GAG extraction and subsequent
laboratory characterization. Indeed, it is only recent
technical advances in the field [27–29] that helped to
identify changes in plasma and urine GAG profiles in other
noncancerous pathologies such as septic shock [30] and
respiratory failure [31]. However, the infancy of these
advances explains the lack of standardized assays commer-
cially available, which may have implications for the results
presented here, as further discussed below.
Our study revealed some unanticipated observations
regarding plasma GAGs in RCC patients. We observed little
to no correlation between the GAG properties used to
compute the new GAG score and tumor stage, grade, and
histology. This seems to indicate that the changes in these
plasma GAG properties are not entirely induced by the
tumor. Simply put, a larger tumor burden did not translate
into larger changes in these GAG properties. In addition,
these GAG properties appeared to be extremely sensitive to
very small tumors in this cohort, in which 39% of RCC
patients had a tumor of <4 cm in size. From a biophysical
perspective, it seems unlikely that such small tumors are
able to affect and maintain the observed GAG alterations in
human circulation. An alternative hypothesis is that an
external factor could respond to RCC at its earliestinception—hence the exceptional sensitivity—and that this
factor is partly responsible for GAG alterations. Such a
response might be elicited by the stroma or the immune
system, given their associationwith plasma GAG changes in
previous studies [32,33]. Another hypothesis is that these
GAG alterations might originate from the tumor and that
the livermaintains plasmaGAGhomeostasis [34,35] despite
changes in the tumor burden. However, this hypothesis
clashes with the observation that GAG scores did not seem
to decrease postoperatively, even though most samples
were taken 4wk after surgery, whichmight not be sufficient
to capture fluctuations after surgery. (For example, pros-
tate-specific antigen testing after radical prostatectomy in
prostate cancer is recommended between 6 and 8 wk after
surgery.) On the contrary, an immune/stromal response
might well be active formonths after surgery and justify the
persistence of the new GAG score. In our previous study, we
observed that GAG scores decreased to normal levels in
eight patients with no evidence of disease, but these
samples were obtained years after the first surgery. If we
assume that the GAG changes observed resulted mostly
because of an external factor, this wouldmake plasma GAGs
a less-than-ideal biomarker according to conventional
criteria because it might affect specificity to RCC [36]. How-
ever, the requirement that ideal biomarkers should origi-
nate from the tumor in order to maximize specificity has
historically yielded poor sensitivity for low-stage tumors, as
recently shown [37]. Low specificity has obvious repercus-
sions if biomarkers are to be applied for early cancer
detection or differential diagnosis, but their high sensitivity
could be useful for other applications important in the
clinical management of RCC, such as surveillance for
recurrence after surgery.
It has been shown that plasma GAGs have potential to
compensate for the lack of minimally invasive biomarkers
in the management of RCC [38] in both nonmetastatic and
metastatic settings. Other biomarkers have shown promis-
ing results in RCC, such as urinary aquaporin-1 (AQP1) and
perlipin-2 (PLIN2) [39–41]. These urinary proteins
had  95% sensitivity and  91% specificity for RCC com-
pared to patients undergoing routine abdominal computed
tomography [41]. AQP1 and PLIN2 changes seem to
originate specifically from RCC [39,41]. It is unknown if
AQP1 and PLN1 levels are independent prognostic factors in
RCC, as observed here for plasma GAGs. Plasma GAG scores
and urinary AQP1 and PLN1 seem to be complementary in
their utility as optimally sensitive and specific minimally
invasive biomarkers.
Despite the clear potential of the GAG score as a
biomarker of direct clinical use, this study has limitations.
Retrospective sample collection may affect GAG concentra-
tions and composition, in that it is unknown whether
sample age is an important factor for GAG stability.
Moreover, slight differences in the sampling protocol
compared to our previous study may have resulted in noise
in the GAG measurements. For example, we previously
centrifuged samples at 2500  g for 15 min at 4 C, while
the current sampleswere centrifuged at 1100  g for 10 min
E U RO P E AN URO L OGY ONCO L OGY 1 ( 2 018 ) 3 6 4 – 37 7376at room temperature, and it is known that a difference in
centrifugal force affects metabolome estimates [42]. Anoth-
er source of noise is the current unavailability of commer-
cial assays for standardized assessment of plasma GAGs.
This noise is probably compensated by the large sample size
and by the fact that all measurements were performed in a
single laboratory. Nevertheless, the presence of noise
warrants validation of the study conclusions in a prospec-
tive cohort with standardized procedures. Finally, we
observed differences between the healthy population in
this study and that in our previous study. Unfortunately,
there is no comprehensive and systematic evaluation of
physiological levels of plasma GAGs in the literature. Most
studies rely on small sample sizes and our study represents
the largest characterization of plasma GAGs in human
samples. It is possible that differences in ethnicity and
lifestyle can lead to different plasma GAG baseline levels in
different populations, as seen in this American cohort when
compared to the Swedish and Italian cohorts in our previous
study. This hypothesis seems corroborated by the fact that
Schmidt et al [31] observed a healthy GAG profile among
American volunteers that was more similar to the healthy
group in the present study, while Mantovani et al [33]
observed a healthy GAG profile among Italian volunteers
that was more similar to the healthy group in our previous
study. Despite these baseline differences, we observed
substantial plasma GAG changes in RCC that were robust to
different populations. A comprehensive evaluation of
plasma GAGs in a large healthy population is nevertheless
required. Finally, the multivariate analysis suggests that
pre-surgical plasma GAGs are associated with metastatic
recurrence independent of tumor stage and thereby could
be used to identify high risk patients across stage groups.
However, the cohort was not powered to validate whether
such association would be still significant in the subset of
RCC with high-stage disease.
5. Conclusions
The results presented here indicate that plasma GAG levels
can provide accurate diagnostic and prognostic information
that may have clinical utility in the management of
nonmetastatic RCC. Plasma GAG alterations appear to
originate as a response to the tumor and occur early if
not concomitantly with tumor formation, and probably
independent of its progression. This warrants prospective
studies on clinical applications for which the simplicity of
blood-based biomarkers and the sensitivity of GAGs can
contribute to extending or improving the survival outlook
for RCC patients.
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